Spots Global Cancer Trial Database for Enzalutamide Before Surgery in Treating Patients With Kidney Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Enzalutamide Before Surgery in Treating Patients With Kidney Cancer

Official Title: Pilot Study of the Blockade of Androgens in Renal Cell Carcinoma Using Enzalutamide (BARE)

Study ID: NCT02885649

Conditions

Clear Cell Renal Cell Carcinoma

Stage I Renal Cell Cancer

Interventions

Enzalutamide

Laboratory Biomarker Analysis

Nephrectomy

Study Description

Brief Summary: This pilot phase 0 trial studies how well enzalutamide works before surgery in treating patients with kidney cancer. Androgens are a type of hormone produced by the body that may cause kidney tumors to grow. Anti-hormone therapy, such as enzalutamide, may lessen the amount of androgens produced by the body and keep kidney tumors from growing.

Detailed Description: PRIMARY OBJECTIVES: I. To investigate the effects of neoadjuvant enzalutamide on clear cell renal cell carcinoma (ccRCC). OUTLINE: Patients receive enzalutamide orally (PO) daily for 90 days in the absence of disease progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy. After completion of study treatment, patients are followed up every 3 months.